Loading...
XTAI
1762
Market cap73mUSD
Jul 14, Last price  
27.60TWD
1D
-0.54%
1Q
-2.13%
Jan 2017
2.03%
IPO
-56.26%
Name

Chunghwa Chemical Synthesis & Biotech Co Ltd

Chart & Performance

D1W1MN
P/E
40.37
P/S
1.59
EPS
0.68
Div Yield, %
8.70%
Shrs. gr., 5y
-0.86%
Rev. gr., 5y
3.10%
Revenues
1.35b
-35.42%
1,126,848,0001,197,243,0001,200,576,0001,329,584,0001,043,480,000946,704,0001,162,211,0001,198,670,0001,168,248,0001,019,452,0001,156,642,0001,543,589,0001,934,702,0002,117,144,0002,086,440,9991,347,375,000
Net income
53m
-79.98%
245,105,000187,004,000170,994,000175,564,00096,825,00014,592,000308,356,00060,283,00085,766,000234,251,000117,003,000531,873,000400,778,000465,865,000264,909,00053,032,000
CFO
468m
P
462,069,000275,614,000144,843,000268,465,000145,240,00023,081,00079,705,000261,313,000159,339,000234,664,000268,128,000138,235,000219,179,000733,779,000-77,503,000467,654,000
Dividend
Jul 26, 20240.8 TWD/sh
Earnings
Aug 04, 2025

Profile

Chunghwa Chemical Synthesis & Biotech Co., Ltd. engages in the research, development, manufacture, and wholesale of active pharmaceutical ingredients (APIs) in Taiwan and the United States. It offers API products, which include immunosuppressant, oncology, cardiovascular, and other products, as well as peptide drugs. The company also develops bulk pharmaceutical products, such as anti-anxiety agents, antidiabetics, laxatives, antifungals, antihistamines, antiseptics, antiulcerants, cardiovascular drugs, skeletal, muscle relaxants, hypolipaemics, antineoplastic, antihyperlipedemias, and immunosuppressant products, as well as provides research and development, and contract manufacturing services to new drug developers and generic drug companies. The company was formerly known as China Chemical Synthesis Industry Co., Ltd. Chunghwa Chemical Synthesis & Biotech Co., Ltd. was founded in 1964 and is headquartered in New Taipei City, Taiwan.
URL
http://www.ccsb.com.tw/
IPO date
Dec 10, 2009
Employees
Domiciled in
TW
Incorporated in
TW

Valuation

Title
TWD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
1,347,375
-35.42%
2,086,441
-1.45%
2,117,144
9.43%
Cost of revenue
1,341,033
1,805,632
1,671,957
Unusual Expense (Income)
NOPBT
6,342
280,809
445,187
NOPBT Margin
0.47%
13.46%
21.03%
Operating Taxes
4,190
68,578
117,165
Tax Rate
66.07%
24.42%
26.32%
NOPAT
2,152
212,231
328,022
Net income
53,032
-79.98%
264,909
-43.14%
465,865
16.24%
Dividends
(62,048)
(100,828)
(100,828)
Dividend yield
2.44%
2.25%
1.96%
Proceeds from repurchase of equity
BB yield
Debt
Debt current
154,189
504,645
103,824
Long-term debt
710,864
712,298
503,983
Deferred revenue
12,743
26,995
500,000
Other long-term liabilities
(500,000)
Net debt
642,778
(47,107)
(701,761)
Cash flow
Cash from operating activities
467,654
(77,503)
733,779
CAPEX
(103,085)
(451,551)
(376,184)
Cash from investing activities
(100,099)
(461,324)
(376,184)
Cash from financing activities
(415,721)
496,574
(253,318)
FCF
347,164
(680,090)
273,847
Balance
Cash
222,275
269,569
300,614
Long term investments
994,481
1,008,954
Excess cash
154,906
1,159,728
1,203,711
Stockholders' equity
2,499,911
2,519,689
2,859,273
Invested Capital
4,072,945
3,426,615
2,543,873
ROIC
0.06%
7.11%
13.14%
ROCE
0.14%
5.80%
11.12%
EV
Common stock shares outstanding
74,900
78,092
78,500
Price
33.90
-40.94%
57.40
-12.50%
65.60
1.08%
Market cap
2,539,110
-43.35%
4,482,481
-12.95%
5,149,600
1.31%
EV
3,181,888
4,435,374
4,448,025
EBITDA
205,498
473,814
614,236
EV/EBITDA
15.48
9.36
7.24
Interest
21,285
19,439
9,712
Interest/NOPBT
335.62%
6.92%
2.18%